

Monday, 6 June 2022

## RESPONSE TO MARKET ENQUIRES

In response to market enquiries, Australian Clinical Labs Limited (ASX: ACL) (**ACL** or the **Company**) confirms based on unaudited management information to 31 May 2022:

- ACL does not expect revenue for the period 1 January to 31 May 2022 to be down more than 1% on the previous corresponding period (excluding revenue from COVID and acquisitions);
- ACL does not expect to depart materially from Bloomberg forecasts for NPAT for the full financial year to 30 June 2022 (excluding acquisition transaction costs).

– ENDS –

This announcement was authorised for release to ASX by the Board of Directors of ACL.

For further information regarding this announcement, please contact:

### Investors

Davina Gunn  
Investor Relations  
Email: [investors@clinicallabs.com.au](mailto:investors@clinicallabs.com.au)  
Phone: +61 (0) 400 896 809

### Media

Sue Cato  
Media Relations  
Email: [cato@catoandclive.com](mailto:cato@catoandclive.com)  
Phone: +61 (0) 2 8306 4244

### About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 80 NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

### Forward looking-statements

This announcement may contain forward-looking statements which are statements that may be identified by words such as "may", "will", "would", "should", "could", "believes", "estimates", "expects", "intends", "plans", "anticipates", "predicts", "outlook", "forecasts", "guidance" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this announcement, are expected to take place. No person who has made any forward-looking statements in this announcement (including the Company) has any intention to update or revise forward-looking statements, or to publish prospective financial information in

the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the directors and management of the Company. The Company cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.